A Study of Ramucirumab (IMC-1121B) With Paclitaxel and Carboplatin in Non-small Cell Lung Cancer
A Phase 2, Open-label Study of IMC-1121B in Combination With Paclitaxel and Carboplatin as First-line Therapy in Patients With Stage IIIB/IV Non-small Cell Lung Cancer
研究概览
详细说明
Non-small cell lung cancer (NSCLC) accounts for 75-80% of all lung cancers. The advanced stages are associated with poor survival rates, a median survival rate of approximately 3.9 months if left untreated.
Angiogenesis is a process for wound healing and restoring blood flow to tissues after injury. It is the physiological process involving the growth of new blood vessels from pre-existing vessels. Angiogenesis may be promoted by growth factors and in diseases such as cancer, where growth factors are over expressed, the body loses the ability to maintain a balanced angiogenesis. This may embellish the existing supplies of blood; potentially increasing the delivery of oxygen and nutrients supplies for cancer growth and survival.
Ramucirumab is an angiogenesis inhibitor; and is believed to block the promotion of the growth factor to form new blood vessels, thus reducing the blood supply to the cancer cells.
研究类型
注册 (实际的)
阶段
- 阶段2
联系人和位置
学习地点
-
-
California
-
Beverly Hills、California、美国、90211
- ImClone Investigational Site
-
San Francisco、California、美国、94143
- ImClone Investigational Site
-
-
Colorado
-
Aurora、Colorado、美国、80045
- ImClone Investigational Site
-
-
New York
-
Bronx、New York、美国、10467
- ImClone Investigational Site
-
New York、New York、美国、10016
- ImClone Investigational Site
-
-
Texas
-
San Antonio、Texas、美国、78229
- ImClone Investigational Site
-
-
Washington
-
Seattle、Washington、美国、98104
- ImClone Investigational Site
-
-
-
-
-
Cambridge、英国
- ImClone Investigational Site
-
London、英国
- ImClone Investigational Site
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Histologically or cytologically confirmed NSCLC
- Advanced NSCLC
- Measurable disease (as defined by Response Evaluation Criteria in Solid Tumors [RECIST 1.0])
- Eastern Cooperative Oncology Group (ECOG) Performance Status is ≤ 1
- Age ≥ 18 years
- Adequate hematologic function = an absolute neutrophil count (ANC) ≥ 1500/μL, hemoglobin ≥ 9 g/dL, and a platelet count ≥ 100,000/microliter (μL)
- Adequate hepatic function = a total bilirubin ≤ 1.5 mg/dL transaminases and alkaline phosphatase ≤ 5 x the upper limit of normal (ULN)
- Adequate renal function serum creatinine ≤ 1.5 x ULN or calculated creatinine clearance (CrCl) > 60 mL/minute, and urine dipstick for protein < 1+ (ie, either 0 or trace)
- Adequate coagulation function, INR ≤ 1.5 and a partial thromboplastin time (PTT) ≤ 5 seconds above ULN
- Adequate contraception
- Signed informed consent
Exclusion Criteria:
- Untreated CNS metastases
- Prior bevacizumab therapy
- Radiologically documented evidence of major blood vessel invasion or encasement by cancer
- Prior systemic chemotherapy for Stage IIIB/IV NSCLC
- Prior systemic chemotherapy or radiation therapy for Stage I-IIIA NSCLC < 1 year prior
- Any concurrent malignancy other than basal cell skin cancer, or carcinoma in situ of the cervix
- Concurrent treatment with other anticancer therapy, including other chemotherapy, immunotherapy, hormonal therapy, radiotherapy, chemoembolization, or targeted therapy
- Ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
- Uncontrolled thrombotic or hemorrhagic disorders
- Poorly-controlled hypertension
- Chronic daily treatment with aspirin (> 325 mg/day) or other known inhibitors of platelet function
- History of gross hemoptysis (defined as bright red blood or ≥ 1/2 teaspoon)
- Serious non-healing wound, ulcer, or bone fracture
- Undergone major surgery or subcutaneous venous access device placement. Post-operative bleeding complications or wound complications from a surgical procedures performed in the last 2 months
- Elective or a planned major surgery to be performed during the course of the trial
- Peripheral neuropathy ≥ Grade 2 (National Cancer Institute Common Toxicity Criteria for Adverse Events, Version 3.0 [NCI-CTCAE v 3.0])
- If female, is pregnant or lactating
- Radiographic evidence of intratumor cavitation
- Grade 3-4 gastrointestinal bleeding within 3 months prior to study entry
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:ramucirumab + paclitaxel + carboplatin
Participants will receive ramucirumab in combination with paclitaxel and carboplatin until disease progression, the development of an unacceptable toxicity, or other withdrawal criteria, for up to six cycles (3 weeks per cycle). In the absence of any withdrawal criteria, participants will continue to receive ramucirumab monotherapy every 3 weeks, provided there is ongoing evidence of benefit upon review every 6 weeks. |
10 milligrams per kilogram (mg/kg), intravenous (IV) infusion, on Day 1 of each 21-day cycle.
其他名称:
200 milligrams per meter squared (mg/m^2), administered intravenously (IV) following the ramucirumab infusion, on day 1 of each 21-day cycle, for up to six cycles.
Administered after paclitaxel, as an intravenous infusion (IV), over 30 minutes on day 1 of each 21-day cycle, for up to six cycles.
The dose to be administered is calculated based on the participant's actual body weight at time of treatment and the area under the curve (AUC) dosing.
The target AUC for carboplatin treatment is AUC=6.
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Percentage of Participants Who Are Progression-free (PFS) at 6 Months
大体时间:6 months
|
Data presented are the percentage of participants without disease progression or death at 6 months.
Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0).
Progressive disease was defined as having at least a 20% increase in sum of longest diameter of target lesions or the appearance of one or more new lesions and/or unequivocal progression of existing nontarget lesions.
|
6 months
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Summary of Participants Reporting Adverse Events
大体时间:Baseline up to 32.5 months
|
Data presented are the number of participants who experienced ramucirumab related treatment-emergent adverse events (TEAE), treatment related serious adverse events (SAE), or any Grade 3 or higher TEAE; any TEAE leading to discontinuation of ramucirumab treatment, and any TEAE leading to dose modification ramucirumab.
A summary of SAEs and other nonserious AEs, regardless of causality, is located in the Reported Adverse Event section.
|
Baseline up to 32.5 months
|
|
Percentage of Participants With Complete Response (CR) or Partial Response (PR) (Objective Response Rate ([ORR])
大体时间:First dose to measured progressive disease or death due to any cause up to 32.5 months
|
Objective response is Complete Response (CR) + Partial Response (PR), as classified by the investigators according to the Response Evaluation Criteria In Solid Tumors (RECIST 1.0) guidelines.
CR is a disappearance of all target and non-target lesions; PR is at least a 30% decrease in the sum of the longest diameter of target lesions without new lesions and progression of non-target lesions.
Objective response rate is calculated as a total number of participants with CR or PR divided by the total number of participants with measurable disease, multiplied by 100.
|
First dose to measured progressive disease or death due to any cause up to 32.5 months
|
|
Duration of Response
大体时间:First dose up to 32.5 months
|
The duration of a complete response (CR) or partial response (PR) was defined as the time from first objective status assessment of CR or PR to the first time of progression, initiation of additional antitumor therapy is first reported, or death as a result of any cause.
CR was defined as the disappearance of all target lesions.
PR was defined as having at least a 30% decrease in sum of longest diameter of target lesions.
|
First dose up to 32.5 months
|
|
Overall Survival (OS) at 1 Year
大体时间:First dose to 1 year
|
Data presented are the percentage of participants surviving at least 12 months after first dose of study medication.
|
First dose to 1 year
|
|
Progression-free Survival (PFS)
大体时间:First dose to measured progressive disease or death due to any cause, up to 32.5 months
|
Defined as the time from date of first dose of study medication to the first documented disease progression as defined by Response Evaluation Criteria In Solid Tumors (RECIST 1.0), initiation of additional antitumor therapy was first reported or death due to any cause. Participants who did not progress, who discontinued treatment for toxicity or a reason other than documented progression, or who were lost to follow-up before documented progression or death were censored at date of last tumor assessment. Participants who started new therapeutic anticancer treatment prior to documented progression or death were censored at date of last tumor assessment prior to new therapeutic anticancer therapy. |
First dose to measured progressive disease or death due to any cause, up to 32.5 months
|
|
Overall Survival (OS)
大体时间:First dose to death due to any cause, up to 32.5 months
|
Overall survival is defined as the time from the first dose of study medication to the date of death from any cause.
Participants who were alive at the end of the follow-up period or lost to follow-up were censored on the last date the patient was known to be alive.
|
First dose to death due to any cause, up to 32.5 months
|
|
Serum Anti-Ramucirumab Antibody Assessment
大体时间:Week 15 (Cycle 5)
|
The number of participants who developed treatment emergent antibody responses to ramucirumab after baseline.
|
Week 15 (Cycle 5)
|
|
Maximum Concentration of Ramucirumab (Cmax)
大体时间:Week 18 (Cycle 6), at 1-Hour Post End of Infusion
|
Week 18 (Cycle 6), at 1-Hour Post End of Infusion
|
合作者和调查者
研究记录日期
研究主要日期
学习开始
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计)
研究记录更新
最后更新发布 (估计)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.